By Mill Chart
Last update: Dec 20, 2023
Our stock screener has spotted ALKERMES PLC (NASDAQ:ALKS) as a growth stock which is not overvalued. NASDAQ:ALKS is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:ALKS has earned a 7 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:ALKS, the assigned 8 reflects its valuation:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:ALKS, the assigned 6 for health provides valuable insights:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:ALKS, the assigned 6 is a significant indicator of profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of ALKS for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
ALKERMES PLC
NASDAQ:ALKS (4/26/2024, 7:00:00 PM)
After market: 24.68 0 (0%)24.68
+0.24 (+0.98%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.